Yashoda Super Specialty Kaushambi
The Subject Expert Committee of Drugs Controller General of India (DCGI) on Wednesday recommended Serum Institute’s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients.
“An expert panel of India’s central drug authority on Wednesday recommended granting of market authorisation to Serum Institute of India (SII) indigenously-developed India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer”, said a source.
The vaccine has been recommended for cervical cancer patients those above 9 years to 26 years of age for both male and female.According to the source, an application has also been sent to the National Technical Advisory Group on Immunisation (NTAGI).
The NTAGI may take the final decision on the HPV vaccine in the next meeting scheduled to be held on June 29.
Amid the reports of exporting unapproved combinations of the drugs to West African countries leading…
Underlining that Orthodontic practices are currently facing numerous challenges and one of the most significant…
The Indian Society of Extra-Corporeal Technology (ISECT) is celebrating its 25th Silver Jubilee National Conference…
The All India Institute of Medical Sciences (AIIMS) has introduced a state-of-the-art ward in its…
Ozone therapy, a groundbreaking healthcare advancement, is rapidly gaining recognition for its potential in revolutionizing…
Providing a big relief to the rheumatology patients at the hospital, All India Institute Medical…